NASDAQ:PRPO Precipio Q3 2024 Earnings Report $6.03 -0.70 (-10.40%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$6.14 +0.11 (+1.82%) As of 04/25/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History Precipio EPS ResultsActual EPS-$0.42Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APrecipio Revenue ResultsActual Revenue$5.21 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APrecipio Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsPrecipio's next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules. Conference Call ResourcesConference Call AudioConference Call TranscriptQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Precipio Q3 2024 Earnings Call TranscriptProvided by QuartrNovember 18, 2024 ShareLink copied to clipboard.There are 2 speakers on the call. Operator00:00:00Please note that the conference is being recorded. Statements made during this call contain forward looking statements about our business. Operator00:00:07You should not place undue reliance on forward looking statements as these statements are based upon our current expectations, forecasts and assumptions and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward looking statements include, but are not limited to, the matters listed under Risk Factors in our annual report on Form 10 ks for the year ended December 30, 2022, which is on file with the Securities and Exchange Commission as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward looking statements, speak only to the date they are provided, unless an earlier date is indicated and we do not undertake any obligation to publicly update any statements or information, including forward looking statements whether as a result of new information, future events or otherwise, except as required by law. Operator00:01:27Now, let me hand the call over to Ilan Daniele, Precipio's CEO. Please go ahead, sir. Speaker 100:01:34Thank you and good afternoon. Thank you all for joining our 2024 Q3 shareholder update call. Thanks to all those who submitted questions. As always, we'll do our best to address them during this call. Before we jump into the numbers, I'd like to take a moment to remind everyone of the business we're in and the impact we have. Speaker 100:01:51We recently crossed the 10,000 case mark for the year, compared to close to 8,000 in 2023. For us, those aren't just numbers that translate into revenue and share price. These are real people, parents and grandparents, siblings and children who have to deal with the awful battle against cancer. I'm really proud of the impact we have on those patients and their families' lives and as we execute on our mission to battle misdiagnosis. I can assure you that many of those 10,000 people are better off because they were diagnosed by our company. Speaker 100:02:23Now let's jump into the business performance. At the end of last year, we declared our goal of reaching breakeven in 2024. Beyond bringing the business to this important successful operational milestone of a company that starts making money, the objective reflects our commitment to avoid raising dilutive structured capital and to bring the company into a new era, we are able to deliver appreciation and shareholder value. I'm pleased to report that our Q3 results demonstrate that we are well on track to achieve our goal this year. Let's review each of the division's performances in a bit more detail, starting with the pathology division. Speaker 100:02:58For the 2nd consecutive quarter, our pathology revenues exceeded the division breakeven point and at $4,500,000 per quarter represents a robust 18% increase from the previous quarter of Q2. We're going to continue to grow this division organically with our existing sales team and our goal is to reach approximately $20,000,000 run rate for this division and remain above that. This creates a division that does 2 key things for our company. First, the division will generate positive cash flow. 2nd, it provides a self sustained, cost free R and D platform that enables us to support our product customers and build our next generation of products, which is the future growth engine of the company. Speaker 100:03:40Our current sales team of 5 members enabled us to deliver this revenue. We may be hiring 1 more salesperson to provide additional revenue stability, so we remain well above that breakeven point. I'm really proud of the team, both our commercial team and our lab operations for their contributions to reaching this point. I know of no other lab that can reach breakeven at these revenue levels. Indeed, if you look at some of the other competitors in the lab services market, even at revenues tenfold hours, they're still struggling to generate cash. Speaker 100:04:10This is a testament to our efficiency of operations, the quality of our service and our business structure that enables us to achieve this financial milestone. I'm also confident that with the current team, the division will remain in this position ensuring that the pathology services will continue to serve as a positive operational and financial contributor to our broader strategy. Moving along to the Products division. Although this division has not yet hit breakeven, we are making steady progress and moving closer. Q3 revenues increased by 13% over Q2, reaching $680,000 As we discussed, we're building a robust customer pipeline, among which we have 3 key customers who are in various onboarding stages. Speaker 100:04:52We anticipate that in this 3rd quarter as well as in the next quarter, we're going to see the full weight of those 3 customers as they onboard our products and that's going to have a significant impact on the division's performance. Going forward, this division is going to become the main engine of growth for our business and as one, let me recap and remind you of the three reasons for that. Number 1, recurring revenue. The products generate consistent reliable income streams unlike the variability of the pathology division. Number 2, customer retention. Speaker 100:05:26Product customers are committed to this pathology, which means there is less likelihood of customer turnover, which in turn contributes to stable and predictable revenue generated. And the last point is margins. The margins for our products are significantly higher than those generated by the product the Pathology Services division. Developing products require R and D investments, which in our case, thanks to our Pathology division, is relatively minimal. Cellarum requires less overhead, simpler operational complexity and a small sales force and less management attention. Speaker 100:05:57This results in a far higher contribution to the bottom line from the products division. The product commercial team consists of 3 members and for the foreseeable future, we intend to keep this small team as is. The strategy is to leverage our distribution channel and ultimately reach their full potential. To this date, the majority of our revenues is from direct sales, but going forward, we expect to see a gradual shift increasing the share of revenue that's generated by our distributors. Although our distributors receive 20% of the margin, we in turn gain access to hundreds of sales reps that are not on our payroll and have access to essentially every customer in the country. Speaker 100:06:36But with that access supported by the brand and reach of these distributors, we're able to get in front of many more customers than we would have likely achieved having gone direct the direct sales route. Moving to our cash position. In terms of our cash position, as you saw in our filings, our change in cash balance from the end of Q2 to the end of Q3 was $226,000 in cash burn. This is compared to approximately $1,000,000 of cash burn during the same period in 2023, a reduction of 75% in cash burn. I don't think there is a better metric to show you the impact of our company growth and improved performance than our cash position as we are rapidly approaching breakeven. Speaker 100:07:18With our current quarterly performance and our cash balance, at this point management sees no need for capital raises. With our current market cap, we remain committed to building cash reserves through our organic growth and customer sales, avoiding shareholder dilution. This is a very exciting time for us. Our team is working tirelessly to achieve the goal of financial independence, and it's exciting to see it within reach. Turning the corner from survival mode to build mode is going to be a very refreshing change for us and we're ready to embrace this new chapter building on the strong foundation we've established. Speaker 100:07:55Some of the questions we received revolved around how to translate the company business performance into future shareholder value. In our analysis, up until now, two main things have held us back, and I'd like to address both. Number 1 is the risk of continued capital raises, and the second is the lack of education of our company vision and market opportunity within the investor community. I think we've reached a turning point in addressing the first concern. With our business performance, progress toward breakeven and cash reserves, we are now in a position where capital raises to cover cash burn as we've done in the past are no longer necessary. Speaker 100:08:32This marks a significant step forward and we can confidently say that this challenge is behind us. As to the lack of education about our company, this is going to change next year. Once the company has achieved several consecutive strong performance quarters, we will then be able to point back to both solid past performance as well as provide investors with insights into what they can expect. This will be done through management guidance on certain parameters such as revenues and EBITDA performance going forward. Our plan also includes participating in investor conferences, building analyst coverage and other investor related activities that will help provide more visibility to the company. Speaker 100:09:13That alongside solid consistent growth and performance, meeting and exceeding our guidance should hopefully provide a substantial boost to our visibility, increasing trading volume and ultimately impact our share price, adjusting the market cap to revenue multiples higher than the current split. In summary, it's really exciting to see the company approach these milestones. We have been through a loss and as Vincent Giorgio said, if you're going through hell, keep going and we did. I think we can end the year strong and go into next year even stronger. With the holidays approaching, I want to wish everyone a joyous holiday season with family and friends and a Happy New Year to everyone. Speaker 100:09:53I'd like to thank you all for your support and I look forward to connecting with you in our next call in 2025. Happy holidays and have a nice evening. Thank you. Operator00:10:03The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallPrecipio Q3 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsQuarterly report(10-Q) Precipio Earnings HeadlinesPrecipio trading halted, volatility trading pauseApril 24 at 11:59 PM | markets.businessinsider.comEarnings call transcript: Precipio Q4 2024 sees revenue growth, strategic shiftsApril 2, 2025 | investing.comTrump’s Secret Social Security Plan?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 26, 2025 | Paradigm Press (Ad)Precipio Inc (PRPO) Q4 2024 Earnings Call Highlights: Break-Even Achieved and Strategic Growth ...April 2, 2025 | finance.yahoo.comPrecipio, Inc. (NASDAQ:PRPO) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comPrecipio Reports Positive Q4 Financial ResultsApril 1, 2025 | tipranks.comSee More Precipio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email. Email Address About PrecipioPrecipio (NASDAQ:PRPO), a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.View Precipio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 2 speakers on the call. Operator00:00:00Please note that the conference is being recorded. Statements made during this call contain forward looking statements about our business. Operator00:00:07You should not place undue reliance on forward looking statements as these statements are based upon our current expectations, forecasts and assumptions and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward looking statements include, but are not limited to, the matters listed under Risk Factors in our annual report on Form 10 ks for the year ended December 30, 2022, which is on file with the Securities and Exchange Commission as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward looking statements, speak only to the date they are provided, unless an earlier date is indicated and we do not undertake any obligation to publicly update any statements or information, including forward looking statements whether as a result of new information, future events or otherwise, except as required by law. Operator00:01:27Now, let me hand the call over to Ilan Daniele, Precipio's CEO. Please go ahead, sir. Speaker 100:01:34Thank you and good afternoon. Thank you all for joining our 2024 Q3 shareholder update call. Thanks to all those who submitted questions. As always, we'll do our best to address them during this call. Before we jump into the numbers, I'd like to take a moment to remind everyone of the business we're in and the impact we have. Speaker 100:01:51We recently crossed the 10,000 case mark for the year, compared to close to 8,000 in 2023. For us, those aren't just numbers that translate into revenue and share price. These are real people, parents and grandparents, siblings and children who have to deal with the awful battle against cancer. I'm really proud of the impact we have on those patients and their families' lives and as we execute on our mission to battle misdiagnosis. I can assure you that many of those 10,000 people are better off because they were diagnosed by our company. Speaker 100:02:23Now let's jump into the business performance. At the end of last year, we declared our goal of reaching breakeven in 2024. Beyond bringing the business to this important successful operational milestone of a company that starts making money, the objective reflects our commitment to avoid raising dilutive structured capital and to bring the company into a new era, we are able to deliver appreciation and shareholder value. I'm pleased to report that our Q3 results demonstrate that we are well on track to achieve our goal this year. Let's review each of the division's performances in a bit more detail, starting with the pathology division. Speaker 100:02:58For the 2nd consecutive quarter, our pathology revenues exceeded the division breakeven point and at $4,500,000 per quarter represents a robust 18% increase from the previous quarter of Q2. We're going to continue to grow this division organically with our existing sales team and our goal is to reach approximately $20,000,000 run rate for this division and remain above that. This creates a division that does 2 key things for our company. First, the division will generate positive cash flow. 2nd, it provides a self sustained, cost free R and D platform that enables us to support our product customers and build our next generation of products, which is the future growth engine of the company. Speaker 100:03:40Our current sales team of 5 members enabled us to deliver this revenue. We may be hiring 1 more salesperson to provide additional revenue stability, so we remain well above that breakeven point. I'm really proud of the team, both our commercial team and our lab operations for their contributions to reaching this point. I know of no other lab that can reach breakeven at these revenue levels. Indeed, if you look at some of the other competitors in the lab services market, even at revenues tenfold hours, they're still struggling to generate cash. Speaker 100:04:10This is a testament to our efficiency of operations, the quality of our service and our business structure that enables us to achieve this financial milestone. I'm also confident that with the current team, the division will remain in this position ensuring that the pathology services will continue to serve as a positive operational and financial contributor to our broader strategy. Moving along to the Products division. Although this division has not yet hit breakeven, we are making steady progress and moving closer. Q3 revenues increased by 13% over Q2, reaching $680,000 As we discussed, we're building a robust customer pipeline, among which we have 3 key customers who are in various onboarding stages. Speaker 100:04:52We anticipate that in this 3rd quarter as well as in the next quarter, we're going to see the full weight of those 3 customers as they onboard our products and that's going to have a significant impact on the division's performance. Going forward, this division is going to become the main engine of growth for our business and as one, let me recap and remind you of the three reasons for that. Number 1, recurring revenue. The products generate consistent reliable income streams unlike the variability of the pathology division. Number 2, customer retention. Speaker 100:05:26Product customers are committed to this pathology, which means there is less likelihood of customer turnover, which in turn contributes to stable and predictable revenue generated. And the last point is margins. The margins for our products are significantly higher than those generated by the product the Pathology Services division. Developing products require R and D investments, which in our case, thanks to our Pathology division, is relatively minimal. Cellarum requires less overhead, simpler operational complexity and a small sales force and less management attention. Speaker 100:05:57This results in a far higher contribution to the bottom line from the products division. The product commercial team consists of 3 members and for the foreseeable future, we intend to keep this small team as is. The strategy is to leverage our distribution channel and ultimately reach their full potential. To this date, the majority of our revenues is from direct sales, but going forward, we expect to see a gradual shift increasing the share of revenue that's generated by our distributors. Although our distributors receive 20% of the margin, we in turn gain access to hundreds of sales reps that are not on our payroll and have access to essentially every customer in the country. Speaker 100:06:36But with that access supported by the brand and reach of these distributors, we're able to get in front of many more customers than we would have likely achieved having gone direct the direct sales route. Moving to our cash position. In terms of our cash position, as you saw in our filings, our change in cash balance from the end of Q2 to the end of Q3 was $226,000 in cash burn. This is compared to approximately $1,000,000 of cash burn during the same period in 2023, a reduction of 75% in cash burn. I don't think there is a better metric to show you the impact of our company growth and improved performance than our cash position as we are rapidly approaching breakeven. Speaker 100:07:18With our current quarterly performance and our cash balance, at this point management sees no need for capital raises. With our current market cap, we remain committed to building cash reserves through our organic growth and customer sales, avoiding shareholder dilution. This is a very exciting time for us. Our team is working tirelessly to achieve the goal of financial independence, and it's exciting to see it within reach. Turning the corner from survival mode to build mode is going to be a very refreshing change for us and we're ready to embrace this new chapter building on the strong foundation we've established. Speaker 100:07:55Some of the questions we received revolved around how to translate the company business performance into future shareholder value. In our analysis, up until now, two main things have held us back, and I'd like to address both. Number 1 is the risk of continued capital raises, and the second is the lack of education of our company vision and market opportunity within the investor community. I think we've reached a turning point in addressing the first concern. With our business performance, progress toward breakeven and cash reserves, we are now in a position where capital raises to cover cash burn as we've done in the past are no longer necessary. Speaker 100:08:32This marks a significant step forward and we can confidently say that this challenge is behind us. As to the lack of education about our company, this is going to change next year. Once the company has achieved several consecutive strong performance quarters, we will then be able to point back to both solid past performance as well as provide investors with insights into what they can expect. This will be done through management guidance on certain parameters such as revenues and EBITDA performance going forward. Our plan also includes participating in investor conferences, building analyst coverage and other investor related activities that will help provide more visibility to the company. Speaker 100:09:13That alongside solid consistent growth and performance, meeting and exceeding our guidance should hopefully provide a substantial boost to our visibility, increasing trading volume and ultimately impact our share price, adjusting the market cap to revenue multiples higher than the current split. In summary, it's really exciting to see the company approach these milestones. We have been through a loss and as Vincent Giorgio said, if you're going through hell, keep going and we did. I think we can end the year strong and go into next year even stronger. With the holidays approaching, I want to wish everyone a joyous holiday season with family and friends and a Happy New Year to everyone. Speaker 100:09:53I'd like to thank you all for your support and I look forward to connecting with you in our next call in 2025. Happy holidays and have a nice evening. Thank you. Operator00:10:03The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by